For Release at 6:00am EST July 8, 2004

NEWS – NEWS – NEWS

ANTICANCER INC. RECEIVES SIXTH PATENT ON FLUORESCENCE IMAGING TECHNOLOGY

AntiCancer Inc. of San Diego announced today that it has received its sixth patent in a series from the U.S. Patent and Trademark office covering the use of fluorescent proteins for imaging of cancer, gene expression, stem cells, and other processes in animals as well as humans. The non-invasive imaging technology involves the use of fluorescent proteins from jellyfish, corals, and other bioluminescent animals that are genetically incorporated into cancer cells, stem cells, and other cell types. The fluorescent proteins also can be linked to genes-of-interest to image gene expression. AntiCancer has published approximately 100 scientific articles using this technology.

“The fluorescent proteins are so bright that they enable non-invasive imaging of any process in the mouse that can be linked to expression of a fluorescent protein. AntiCancer’s use of these fluorescent proteins has revolutionized the use of small animals for drug discovery” said AntiCancer spokeswoman, Charlene M. Cooper. “This powerful technology, with multiple colors and single-cell resolution in the animal coupled with AntiCancer’s patent portfolio, places AntiCancer in a unique position of the field of small-animal imaging” said Sheldon Penman, Emeritus Professor of Biology at MIT and member of the National Academy of Sciences.

“AntiCancer’s fluorescence small-animal imaging technology is uniquely enabling for high-throughput in vivo drug discovery and evaluation for all types of diseases. The technology is highly useful for pharmaceutical and biotechnology companies as well as academic researchers” said Spokeswoman Cooper.

AntiCancer, founded in 1984 and based in San Diego, is also developing new drugs based on genetic engineering that target cancer-specific metabolic defects. The company is also developing diagnostics for diseases including cancer. The company is also actively developing genetic and stem-cell approaches to cancer and hair follicle therapy.

For more information, see AntiCancer’s website at www.anticancer.com or contact Charlene M. Cooper via e-mail: all@anticancer.com.

7/15/03